Linked Life Data

16909305

Source:http://linkedlifedata.com/resource/pubmed/id/16909305

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
2007-3-5
pubmed:abstractText
Hepatitis C combination therapy comprising ribavirin and interferon-alpha causes dramatic improvement with the sustained virological response; however, this treatment may result in the loss of bone mineral density. To investigate the effects of ribavirin on bone cells, we examined osteoblast differentiation as well as the formation of osteoclasts from their precursors. Ribavirin enhances osteoclast formation through osteoblasts by up-regulation of TRANCE/RANKL gene expression, whereas it has no significant effect on either osteoblast differentiation or on bone formation. Understanding ribavirin's underlying mechanism of action on bone cells will enable the improved management of bone loss in chronic hepatitis C patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0300-8177
pubmed:author
pubmed:issnType
Print
pubmed:volume
296
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
17-24
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Ribavirin enhances osteoclast formation through osteoblasts via up-regulation of TRANCE/RANKL.
pubmed:affiliation
Research Institute of Medical Sciences, Chonnam National University Medical School, Gwangju, Korea.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't